Articles and Insights About Wearables for Clinical Trials

VivoSense^®3.6 update is live and ready! We are committed to continually expanding its capabilities to provide visualization and analysis for data from wearable sensors in clinical research.

In collaboration with researchers at the University of Massachusetts Amherst, VivoSense published a new review paper in the Journal of Alzheimer’s Disease. The review summarizes how measures of real-world physical behavior, captured with digital health technologies, can contribute to more holistic assessment of functional independence in Alzheimer’s disease clinical research.

On June 7th, 2023, Robert Wright, PhD, Senior Research Scientist at VivoSense, and Jana Von Hehn, PhD, CSO at Rett Syndrome Research Trust, presented at the Digital Health Innovation Summit, a forum to learn from the best about top trends in the industry. Their presentation, Developing Patient-Centric Real-World Digital Clinical Measures for Rett Syndrome, summarized years of collaborative work implementing digital health technologies in complex research programs.

We are thrilled to announce Colin Bower as our new Chief Executive Officer and a member of our Board of Directors. Bower will succeed Dudley Tabakin, who will work closely with Bower to achieve a seamless transition. Tabakin will continue with VivoSense in his new capacity as Chief Product Officer.

We all know it's important to choose "measures that matter" when selecting and developing digital measures for evidence generation in clinical trials, but how do we put these good intentions into action? How do we lay solid, patient-centric foundations, whether that means designing a protocol, building an integrated evidence plan, or qualifying a novel evidence tool?

DATAcc announced the release of the Analytical Validation Library on May 23, 2023! Kate Lyden, Ph.D. and VivoSense CSO collaborated with other industry leaders to show ‘what good looks like’ regarding high-quality analytical validation. As new DHTs come online, industry-wide standards must be developed in tandem to ensure their ability to measure, detect or predict a clinical state.

Jen Blankenship, PhD, Senior Research Scientist, moderated a lively discussion with Shelby Bachman, PhD, Research Scientist, and an expert panel about the promise of Digital health technologies (DHTs) like smartphones and wearable sensors to advancing drug development and discovery in neurodegenerative diseases, particularly Alzheimer’s disease.

In September 2022, a broad range of stakeholders representing regulators, Pharma and Biotech firms, technology service providers, innovators, and patients gathered in Zürich. This meeting, the second in a series hosted by the Swiss Federal Institute of Technology and the Foundation for the National Institutes of Health Biomarkers Consortium, sought to explore the role patient centricity must play in the development and validation of digital tools for gathering evidence. Director of Science Ieuan Clay, a member of the Biomarkers Consortium, represented VivoSense in the discussion examining four case studies of interest:

VivoSense is excited to announce a collaboration with Cambridge Cognition to capture measures of cognitive and physical function using digital health tools. Both organizations are united in their interests to develop low-burden and patient-centric digital clinical outcome measures that more comprehensively and holistically capture how individuals function in real-world environments.

On June 2, 2023, at ASCO, CancerX, a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), along with the Office for the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH), announced its founding members. VivoSense is proud to be among other organizations striving to eradicate cancer!